Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
33%(1 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed375%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruiting

REal-life ON PARKinson's - ITaly (REONPARK-IT)

NCT07403799
completedphase_4

OpiCapone Effect on Motor Fluctuations and pAiN

NCT04986982
completedphase_3

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

NCT04978597
completednot_applicable

Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

NCT06432309

Clinical Trials (4)

Showing 4 of 4 trials
NCT07403799

REal-life ON PARKinson's - ITaly (REONPARK-IT)

Recruiting
NCT04986982Phase 4

OpiCapone Effect on Motor Fluctuations and pAiN

Completed
NCT04978597Phase 3

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Completed
NCT06432309Not Applicable

Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4